Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Genetic Management Algorithm in High-Risk Fabry Disease Cases; Especially in Female Indexes with Mutations

Author(s): Ozlem Sezer* and Serdar Ceylaner

Volume 21, Issue 2, 2021

Published on: 08 July, 2020

Page: [324 - 337] Pages: 14

DOI: 10.2174/1871530320666200708135826

Price: $65

Abstract

Background: Fabry Disease (FD, OMIM#301500) is a progressive, life-threatening, multisystemic, rare lysosomal storage disease. Today, approximately 1000 mutations are recorded in the Human Gene Mutation Database (www.hgmd.org) for GLA. Among the identified mutations, genetic variants of unknown significance (GVUS) and novel mutations cause problems in terms of diagnosis and treatment approach.

Methods: In our study, 510 high-risk patients were enrolled. 229 out of 510 were Male (45%) (Mean age was 40.8 ±15.0) and 281 of were Female (55%) (Mean age was 39, 7±15.5). The definite diagnosis of the FD was confirmed by GLA gene sequence analysis. GLA mutation was found in 15 cases (3.4%). Family members of the relevant indexes were included in the screening programs according to the X-linked inheritance pattern. And then we conducted family screening on 74 family members of 15 index cases. Of those 74 cases, 39 had mutations (53%). In males, α-GalA activity and in both gender Lyso-Gb3 levels were measured and multisystem evaluation was performed in all cases with the mutation.

Results: We found six different familial mutation types; two of them pathogenic; p.D170N (1), p.P205S (13), one of them GVUS; p.Q330R (1), three of them likely benign; p.D313Y (12), p.S126G (25), c.-30G>A (2) mutations were detected.

Conclusion: The purpose of this retrospective study is to approach Fabry disease on a genetic basis and to improve its management and to draw attention to the importance of early diagnosis. We also aimed to evaluate the appropriate algorithms to determine whether the mutation is the FD-causing mutation or not.

Keywords: Fabry, GLA, D313Y, Q330R, S126G, D170N, P205S, -30G>A.

« Previous Next »
Graphical Abstract

[1]
Schiffmann, R.; Hughes, D.A.; Linthorst, G.E.; Ortiz, A.; Svarstad, E.; Warnock, D.G.; West, M.L.; Wanner, C. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int., 2017, 91(2), 284-293.
[http://dx.doi.org/10.1016/j.kint.2016.10.004] [PMID: 27998644]
[2]
Maron, M.S.; Xin, W.; Sims, K.B.; Butler, R.; Haas, T.S.; Rowin, E.J.; Desnick, R.J.; Maron, B.J. Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy. Am. J. Med., 2018, 131(2), 200.e1-200.e8.
[http://dx.doi.org/10.1016/j.amjmed.2017.09.010] [PMID: 28943383]
[3]
Capuano, I.; Garofalo, C.; Buonanno, P.; Pinelli, M.; Di Risi, T.; Feriozzi, S.; Riccio, E.; Pisani, A. Identifying Fabry patients in dialysis population: prevalence of gla mutations by renal clinic screening, 1995–2019. J. Nephrol., 2019, 3(1), 139-145.
[PMID: 31650418]
[4]
Rolfs, A.; Fazekas, F.; Grittner, U.; Dichgans, M.; Martus, P.; Holzhausen, M.; Böttcher, T.; Heuschmann, P.U.; Tatlisumak, T.; Tanislav, C.; Jungehulsing, G.J.; Giese, A.K.; Putaala, J.; Huber, R.; Bodechtel, U.; Lichy, C.; Enzinger, C.; Schmidt, R.; Hennerici, M.G.; Kaps, M.; Kessler, C.; Lackner, K.; Paschke, E.; Meyer, W.; Mascher, H.; Riess, O.; Kolodny, E.; Norrving, B. Acute cerebrovascular disease in the young: the stroke in young Fabry patients study. Stroke, 2013, 44(2), 340-349.
[http://dx.doi.org/10.1161/STROKEAHA.112.663708] [PMID: 23306324]
[5]
Desnick, R.J.; Ioannou, Y.A.; Eng, C.M. α-Galactosidase a deficiency: Fabry disease. The Online Metabolic and Molecular Bases of Inherited Disease; David, Valle, Ed.; McGraw-Hill Med.: New York , 2014.
[6]
Arends, M.; Wanner, C.; Hughes, D.; Mehta, A.; Oder, D.; Watkinson, O.T.; Elliott, P.M.; Linthorst, G.E.; Wijburg, F.A.; Biegstraaten, M.; Hollak, C.E. Characterization of classical and nonclassical Fabry disease: a multicenter study. J. Am. Soc. Nephrol., 2017, 28(5), 1631-1641.
[http://dx.doi.org/10.1681/ASN.2016090964] [PMID: 27979989]
[7]
The Human Gene Mutation Database. Available from: http://www.hgmd. cf.ac.uk/ac/gene.php?gene=GLA
[8]
Laney, D.A.; Bennett, R.L.; Clarke, V.; Fox, A.; Hopkin, R.J.; Johnson, J.; O’Rourke, E.; Sims, K.; Walter, G. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J. Genet. Couns., 2013, 22(5), 555-564.
[http://dx.doi.org/10.1007/s10897-013-9613-3] [PMID: 23860966]
[9]
Laney, D.A.; Fernhoff, P.M. Diagnosis of Fabry disease via analysis of family history. J. Genet. Couns., 2008, 17(1), 79-83.
[http://dx.doi.org/10.1007/s10897-007-9128-x] [PMID: 18172746]
[10]
Lukas, J.; Giese, A.K.; Markoff, A.; Grittner, U.; Kolodny, E.; Mascher, H.; Lackner, K.J.; Meyer, W.; Wree, P.; Saviouk, V.; Rolfs, A. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet., 2013, 9(8)e1003632
[http://dx.doi.org/10.1371/journal.pgen.1003632] [PMID: 23935525]
[11]
Chamoles, N.A.; Blanco, M.; Gaggioli, D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin. Chim. Acta, 2001, 308(1-2), 195-196. [4]
[http://dx.doi.org/10.1016/S0009-8981(01)00478-8] [PMID: 11432396]
[12]
Polo, G.; Burlina, A.P.; Kolamunnage, T.B.; Zampieri, M.; Dionisi-Vici, C.; Strisciuglio, P.; Zaninotto, M.; Plebani, M.; Burlina, A.B. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS. Clin. Chem. Lab. Med., 2017, 55(3), 403-414.
[http://dx.doi.org/10.1515/cclm-2016-0340] [PMID: 27533120]
[13]
ClinVar Database. Available from: https://www.ncbi.nlm.nih.gov/clinvar/?term=gla%5Bgene%5D
[14]
The Fabry disease mutation database.. Available from: http://fabry-database.org/mutants/pkup.cgi
[15]
International Fabry Disease Genotype-Phenotype Database (dbFGP). Available from: http://dbfgp. org/dbFgp/fabry/
[16]
Centogene. Available from: https://www.centogene.com/centolsd.html
[17]
Ortiz, A.; Germain, D.P.; Desnick, R.J.; Politei, J.; Mauer, M.; Burlina, A.; Eng, C.; Hopkin, R.J.; Laney, D.; Linhart, A.; Waldek, S.; Wallace, E.; Weidemann, F.; Wilcox, W.R. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol. Genet. Metab., 2018, 123(4), 416-427.
[http://dx.doi.org/10.1016/j.ymgme.2018.02.014] [PMID: 29530533]
[18]
Ferreira, S.; Reguenga, C.; Oliveira, J.P. The Modulatory Effects of the Polymorphisms in GLA 5′-Untranslated Region Upon Gene Expression Are Cell-Type Specific. JIMD Rep., 2015, 23, 27-34.
[http://dx.doi.org/10.1007/8904_2015_424] [PMID: 25772321]
[19]
Nowak, A.; Mechtler, T.P.; Hornemann, T.; Gawinecka, J.; Theswet, E.; Hilz, M.J.; Kasper, D.C. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol. Genet. Metab., 2018, 123(2), 148-153.
[http://dx.doi.org/10.1016/j.ymgme.2017.07.002] [PMID: 28728877]
[20]
Duro, G.; Zizzo, C.; Cammarata, G.; Burlina, A.; Burlina, A.; Polo, G.; Scalia, S.; Oliveri, R.; Sciarrino, S.; Francofonte, D.; Alessandro, R.; Pisani, A.; Palladino, G.; Napoletano, R.; Tenuta, M.; Masarone, D.; Limongelli, G.; Riccio, E.; Frustaci, A.; Chimenti, C.; Ferri, C.; Pieruzzi, F.; Pieroni, M.; Spada, M.; Castana, C.; Caserta, M.; Monte, I.; Rodolico, M.S.; Feriozzi, S.; Battaglia, Y.; Amico, L.; Losi, M.A.; Autore, C.; Lombardi, M.; Zoccali, C.; Testa, A.; Postorino, M.; Mignani, R.; Zachara, E.; Giordano, A.; Colomba, P. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int. J. Mol. Sci., 2018, 19(12), 3726.
[http://dx.doi.org/10.3390/ijms19123726] [PMID: 30477121]
[21]
Yasuda, M.; Shabbeer, J.; Benson, S.D.; Maire, I.; Burnett, R.M.; Desnick, R.J. Fabry disease: characterization of α-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum. Mutat., 2003, 22(6), 486-492.
[http://dx.doi.org/10.1002/humu.10275] [PMID: 14635108]
[22]
Baptista, M.V.; Ferreira, S. Pinho-E-Melo, T.; Carvalho, M.; Cruz, V.T.; Carmona, C.; Silva, F.A.; Tuna, A.; Rodrigues, M.; Ferreira, C.; Pinto, A.A.; Leitão, A.; Gabriel, J.P.; Calado, S.; Oliveira, J.P.; Ferro, J.M. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients. Stroke, 2010, 41(3), 431-436.
[http://dx.doi.org/10.1161/STROKEAHA.109.570499] [PMID: 20110537]
[23]
Brouns, R.; Thijs, V.; Eyskens, F.; Van den Broeck, M.; Belachew, S.; Van Broeckhoven, C.; Redondo, P.; Hemelsoet, D.; Fumal, A.; Jeangette, S.; Verslegers, W.; Baker, R.; Hughes, D.; De Deyn, P.P. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke, 2010, 41(5), 863-868.
[http://dx.doi.org/10.1161/STROKEAHA.110.579409] [PMID: 20360539]
[24]
Lenders, M.; Duning, T.; Schelleckes, M.; Schmitz, B.; Stander, S.; Rolfs, A.; Brand, S.M.; Brand, E. Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene. PLoS One, 2013, 8(2)e55565
[http://dx.doi.org/10.1371/journal.pone.0055565] [PMID: 23393592]
[25]
Yeniçerioğlu, Y.; Akdam, H.; Dursun, B.; Alp, A.; Sağlam Eyiler, F.; Akın, D.; Gün, Y.; Hüddam, B.; Batmazoğlu, M.; Gibyeli Genek, D.; Pirinççi, S.; Ersoy, İ.R.; Üzüm, A.; Soypaçacı, Z.; Tanrısev, M.; Çolak, H.; Demiral Sezer, S.; Bozkurt, G.; Akyıldız, U.O.; Akyüz Ünsal, A.İ.; Ünübol, M.; Uslu, M.; Eryılmaz, U.; Günel, C.; Meteoğlu, İ.; Yavaşoğlu, İ.; Ünsal, A.; Akar, H.; Okyay, P. Screening Fabry’s disease in chronic kidney disease patients not on dialysis: a multicenter study. Ren. Fail., 2017, 39(1), 104-111.
[http://dx.doi.org/10.1080/0886022X.2016.1254656] [PMID: 27832731]
[26]
Koulousios, K.; Stylianou, K.; Pateinakis, P.; Zamanakou, M.; Loules, G.; Manou, E.; Kyriklidou, P.; Katsinas, C.; Ouzouni, A.; Kyriazis, J.; Speletas, M.; Germenis, A.E. Fabry disease due to D313Y and novel GLA mutations. BMJ Open, 2017, 7(10)e017098
[http://dx.doi.org/10.1136/bmjopen-2017-017098] [PMID: 28988177]
[27]
Gaspar, P.; Herrera, J.; Rodrigues, D.; Cerezo, S.; Delgado, R.; Andrade, C.F.; Forascepi, R.; Macias, J.; del Pino, M.D.; Prados, M.D.; de Alegria, P.R.; Torres, G.; Vidau, P.; Sá-Miranda, M.C. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med. Genet., 2010, 11, 19.
[http://dx.doi.org/10.1186/1471-2350-11-19] [PMID: 20122163]
[28]
Favalli, V.; Disabella, E.; Molinaro, M.; Tagliani, M.; Scarabotto, A.; Serio, A.; Grasso, M.; Narula, N.; Giorgianni, C.; Caspani, C.; Concardi, M.; Agozzino, M.; Giordano, C.; Smirnova, A.; Kodama, T.; Giuliani, L.; Antoniazzi, E.; Borroni, R.G.; Vassallo, C.; Mangione, F.; Scelsi, L.; Ghio, S.; Pellegrini, C.; Zedde, M.; Fancellu, L.; Sechi, G.; Ganau, A.; Piga, S.; Colucci, A.; Concolino, D.; Di Mascio, M.T.; Toni, D.; Diomedi, M.; Rapezzi, C.; Biagini, E.; Marini, M.; Rasura, M.; Melis, M.; Nucera, A.; Guidetti, D.; Mancuso, M.; Scoditti, U.; Cassini, P.; Narula, J.; Tavazzi, L.; Arbustini, E. Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics. J. Am. Coll. Cardiol., 2016, 68(10), 1037-1050.
[http://dx.doi.org/10.1016/j.jacc.2016.05.090] [PMID: 27585509]
[29]
Arends, M.; Biegstraaten, M.; Wanner, C.; Sirrs, S.; Mehta, A.; Elliott, P.M.; Oder, D.; Watkinson, O.T.; Bichet, D.G.; Khan, A.; Iwanochko, M.; Vaz, F.M.; van Kuilenburg, A.B.P.; West, M.L.; Hughes, D.A.; Hollak, C.E.M. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J. Med. Genet., 2018, 55(5), 351-358.
[http://dx.doi.org/10.1136/jmedgenet-2017-104863] [PMID: 29437868]
[30]
Lukas, J.; Scalia, S.; Eichler, S.; Pockrandt, A.M.; Dehn, N.; Cozma, C.; Giese, A.K.; Rolfs, A. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease. Hum. Mutat., 2016, 37(1), 43-51.
[http://dx.doi.org/10.1002/humu.22910] [PMID: 26415523]

Rights & Permissions Print Cite
Article Metrics
22
2
© 2024 Bentham Science Publishers | Privacy Policy